# Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

> **NCT00626158** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 45 (actual)

## Conditions studied

- Pancreatic Cancer
- Biliary Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00626158
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626158, "Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00626158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*